Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 3

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 3
---
 and relative lack of liquidity in our stock, we may not receive any cash proceeds in relation to such Warrants. We will bear all costs, expenses and fees in connection with the registration of these securities, including with regard to compliance with state securities or “blue sky” laws. The Selling Securityholders will bear all commissions and discounts, if any, attributable to their sale of shares of Common Stock. See “ Plan of Distribution.” Our Common Stock is listed on The Nasdaq Global Market under the symbol “LIMN”. Our Public Warrants are listed on The Nasdaq Capital Market under the symbol “LIMNW”. On July 23, 2025, the last reported sales price of our Common Stock was $6.47 per share and the last reported sales price of our Public Warrants was approximately $0.2775 per warrant.

#### ​The shares of Common Stock being registered for resale in this prospectus will constitute a considerable percentage of our “public float” (defined as the number of our outstanding shares of Common Stock held by non-affiliates). In addition, a portion of the shares of Common Stock being registered for resale hereunder were purchased by the Selling Securityholders at prices below the current market price of our Common Stock. Given the substantial amount of redemptions in connection with the Business Combination (see “Prospectus Summary”), and the relative lack of liquidity in our stock, sales of our Common Stock under the registration statement of which this prospectus is a part could result in a significant decline in the market price of our securities.Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading “Risk Factors” beginning on page14of this prospectus, and under similar headings in any amendment or supplements to this prospectus.Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.The date of this prospectus is  __________, 2025.​​
#### ​

TABLE OF CONTENTS

| ​                                                                                                  |   ​ |
| FREQUENTLY USED TERMS                                                                              |   2 |
| ​                                                                                                  |   ​ |
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS                                               |   5 |
| ​                                                                                                  |   ​ |
| PROSPECTUS SUMMARY                                                                                 |   7 |
| ​                                                                                                  |   ​ |
| THE OFFERING